InvestorsHub Logo
Followers 4
Posts 1194
Boards Moderated 0
Alias Born 10/03/2015

Re: ronpopeil post# 556

Thursday, 10/19/2017 4:58:20 PM

Thursday, October 19, 2017 4:58:20 PM

Post# of 977
If you are long TRIL, you want to see how well TTI621 works in lung and ovarian cancers which express high CD47 before you give the company away. I hope they can try a 1 dose IT study in SCLC patients, Pd1 doesn't work in 80% of them.